Adavosertib
Adavosertib is a drug used to treat Advanced Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Cervical Carcinoma, and other conditions. Adavosertib is being actively studied in 18 studies; no studies for this drug have been completed so far.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| National Cancer Institute (NCI) | Dana-Farber Cancer Institute | James Cleary, MD, PhD |
| AstraZeneca | M D Anderson Cancer Center | |
| M.D. Anderson Cancer Center | University of Pittsburgh Cancer Institute (UPCI) |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Not yet recruiting
- Pancreatic Cancer
- Adavosertib
- Gemcitabine
- Boston, MassachusettsDana-Farber Cancer Institute
2022-01-23
Jan 23, 2022A
Active, not recruiting
- Advanced Solid Tumours
- Adavosertib
- Newnan, Georgia
- +14 more
2022-03-15
Mar 15, 2022N
Suspended
- Advanced Malignant Solid Neoplasm
- +3 more
- Adavosertib
- Olaparib
- Houston, TexasM D Anderson Cancer Center
2022-03-31
Mar 31, 2022M
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Adavosertib
- +2 more
- Boston, Massachusetts
- +1 more
2022-03-09
Mar 9, 2022A
Recruiting
- Advanced Solid Tumours
- Adavosertib
- +3 more
- New Haven, Connecticut
- +11 more
2022-03-22
Mar 22, 2022A
Active, not recruiting
- Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
- Adavosertib
- +4 more
- Gilbert, Arizona
- +19 more
2022-02-23
Feb 23, 2022A
Active, not recruiting
- Uterine Serous Carcinoma
- Adavosertib
- Birmingham, Alabama
- +41 more
2021-11-30
Nov 30, 2021M
Recruiting
- Advanced Fallopian Tube Carcinoma
- +21 more
- Adavosertib
- Laboratory Biomarker Analysis
- Portland, Oregon
- +7 more
2022-01-18
Jan 18, 2022N
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Adavosertib
- Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022N
Active, not recruiting
- Anaplastic Astrocytoma
- +5 more
- Adavosertib
- +3 more
- Birmingham, Alabama
- +23 more
2022-01-28
Jan 28, 2022N
Active, not recruiting
- Central Nervous System Embryonal Tumor With Rhabdoid Features
- +14 more
- Adavosertib
- Irinotecan Hydrochloride
- Birmingham, Alabama
- +23 more
2021-09-15
Sep 15, 2021N
Active, not recruiting
- Glioblastoma
- Recurrent Glioblastoma
- Adavosertib
- +2 more
- Birmingham, Alabama
- +11 more
2022-03-15
Mar 15, 2022N
Suspended
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Adavosertib
- Duarte, California
- +8 more
2022-03-15
Mar 15, 2022C
Recruiting
- Prostate Cancer
- Adavosertib
- +6 more
- Edmonton, Alberta, Canada
- +11 more
2022-02-14
Feb 14, 2022N
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- Adavosertib
- +5 more
- Aurora, Colorado
- +7 more
2021-05-06
May 6, 2021N
Suspended
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- +58 more
- Adavosertib
- Radiation Therapy
- Duarte, California
- +6 more
2022-02-24
Feb 24, 2022N
Active, not recruiting
- Metastatic Pancreatic Adenocarcinoma
- +3 more
- Adavosertib
- +5 more
- Chicago, Illinois
- +4 more
2021-06-10
Jun 10, 2021N
Active, not recruiting
- Clear Cell Renal Cell Carcinoma
- +6 more
- Adavosertib
- Orange, California
- +28 more
2022-03-01
Mar 1, 2022N
Active, not recruiting
- Cervical Carcinoma
- +23 more
- Adavosertib
- +2 more
- Sacramento, California
- +7 more
2021-11-09
Nov 9, 2021N
Active, not recruiting
- Ovarian Brenner Tumor
- +11 more
- Adavosertib
- +5 more
- Duarte, California
- +14 more
2022-02-05
Feb 5, 2022N
Terminated
- Acute Myeloid Leukemia
- +10 more
- Adavosertib
- +3 more
- Tampa, Florida
- +1 more
2018-05-24
May 24, 2018N
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +33 more
- Birmingham, Alabama
- +1423 more
2022-04-06
Apr 6, 2022